cis-Platinum-induced hypomagnesemia and peripheral neuropathy

Area of Science:

• Oncology
• Nephrology
• Neuroscience

Background:

• Cis-platinum is a widely used chemotherapeutic agent in gynecologic oncology.
• Peripheral neuropathy is a significant dose-limiting toxicity associated with cis-platinum treatment.
• Electrolyte imbalances, particularly hypomagnesemia, have been anecdotally linked to cis-platinum therapy.

Purpose of the Study:

• To investigate the relationship between cis-platinum administration and serum magnesium levels in gynecologic oncology patients.
• To determine the incidence of hypomagnesemia and its association with peripheral neuropathy.
• To analyze factors influencing cis-platinum-induced hypomagnesemia and neurotoxicity.

Main Methods:

• A cohort of 69 gynecologic oncology patients receiving cis-platinum at 4-week intervals were prospectively studied.
• Serum magnesium levels were monitored before and during cis-platinum treatment.
• Peripheral neuropathy was assessed clinically, and toxicity was closely monitored.

Main Results:

• Forty-one out of 69 patients developed hypomagnesemia.
• Thirty-one patients with hypomagnesemia exhibited signs and symptoms of peripheral neuropathy.
• None of the 16 patients with normal serum magnesium levels showed neurotoxicity.
• Peripheral neuropathy was identified as the primary dose-limiting factor.

Conclusions:

• Cis-platinum treatment is associated with a high incidence of hypomagnesemia in gynecologic oncology patients.
• Hypomagnesemia is strongly correlated with the development of peripheral neuropathy.
• Both hypomagnesemia and peripheral neuropathy induced by cis-platinum are dependent on the cumulative dose received.